21:09 , May 24, 2019 |  BC Extra  |  Company News

AveXis says label makes Zolgensma gene therapy ‘treatment of choice’ for newly diagnosed SMA

Gene therapy Zolgensma from Novartis’ AveXis unit received a label from FDA that will allow it to become the “treatment of choice” for newly diagnosed spinal muscular atrophy patients, according to the company, as well...
18:21 , May 3, 2019 |  BC Week In Review  |  Company News

Express Scripts excludes rare disease drugs Onpattro, Ingrezza

Express Scripts excluded from its 2019 preferred formulary two rare disease therapy, Alnylam's amyloidosis drug Onpattro patisiran and Neurocrine's tardive dyskinesia drug Ingrezza valbenazine. Each are one of two approved drugs in their respective indications....
23:20 , Apr 26, 2019 |  BC Extra  |  Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs. PBMs and insurance companies typically require...
00:23 , Apr 19, 2019 |  BC Week In Review  |  Company News

Amgen launches osteoporosis drug at $21,900 per treatment course

Amgen launched Evenity romosozumab-aqqg in the U.S. at $1,825 per month to treat osteoporosis in postmenopausal women at high risk of fracture. Amgen Inc. (NASDAQ:AMGN) said the list price for a full course of Evenity...
19:50 , Apr 10, 2019 |  BC Extra  |  Politics & Policy

Insulin manufacturers, PBMs spar over rebates and pricing

Insulin manufacturers and PBMs sparred at a congressional hearing Wednesday, blaming each other for escalating list prices of diabetes drugs and offering opposing policy prescriptions. The three companies that manufacture almost all of the insulin...
22:37 , Apr 3, 2019 |  BC Extra  |  Politics & Policy

Express Scripts offers option to cap insulin costs

As congressional pressure mounts on drug companies and PBMs over rising insulin costs, Express Scripts presented clients with a new option Wednesday that could lessen the burden on patients in the near term. Express Scripts...
23:54 , Feb 6, 2019 |  BC Extra  |  Company News

Express Scripts logs lowest increase in drug spending in quarter-century

In its 2018 Drug Trend Report , Express Scripts Holding Co. Inc. (NASDAQ:ESRX) reported that its commercial plans' per-person spending on prescription drugs rose by 0.4% compared with 2017, the lowest rate of increase in...
00:27 , Jan 30, 2019 |  BC Extra  |  Company News

Amgen's guidance comes up short, but migraine drug sales show promise

Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations. The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below...
00:07 , Dec 7, 2018 |  BC Extra  |  Politics & Policy

CMS: drug spending growth lowest in five years

Drug spending increased 0.4% in 2017, the lowest growth rate since 2012, according to a report from CMS’s Office of the Actuary. Healthcare spending grew at a rate of 3.9% last year, showing a reduction...
00:25 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Epclusa, Harvoni first alternatives on Express Scripts' new formulary

Express Scripts Holding Co. (NASDAQ:ESRX) introduced a new formulary Tuesday to help lower out-of-pocket costs and reduce dependence on rebated brand products by including authorized alternative medicines with lower list prices. HCV drugs Epclusa sofosbuvir/velpatasvir...